Provided by Tiger Trade Technology Pte. Ltd.

Guardant Health Inc.

102.07
+0.69000.68%
Post-market: 101.80-0.2700-0.26%19:57 EST
Volume:1.51M
Turnover:153.61M
Market Cap:13.21B
PE:-31.77
High:103.52
Open:103.52
Low:100.47
Close:101.38
52wk High:112.43
52wk Low:29.91
Shares:129.37M
Float Shares:124.00M
Volume Ratio:0.73
T/O Rate:1.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2124
EPS(LYR):-3.5551
ROE:-4584.47%
ROA:-19.64%
PB:-37.25
PE(LYR):-28.71

Loading ...

REFILE-BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Tower Semiconductor, GlobalFoundries

Reuters
·
Nov 11

GH Research price target lowered to $35 from $40 at H.C. Wainwright

TIPRANKS
·
Nov 11

Guardant Health Launches Expanded Reveal Blood Test for Early Cancer Therapy Response Monitoring

Reuters
·
Nov 10

Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring

THOMSON REUTERS
·
Nov 10

U.S. RESEARCH ROUNDUP-DoorDash, Honeywell, Zscaler

Reuters
·
Nov 10

RBC Capital Keeps Their Buy Rating on GH Research (GHRS)

TIPRANKS
·
Nov 08

Cantor Fitzgerald Keeps Their Buy Rating on GH Research (GHRS)

TIPRANKS
·
Nov 07

Positive Outlook on GH Research Amidst Clinical Challenges and Future Growth Potential

TIPRANKS
·
Nov 07

Guardant Health to Participate in Jefferies Global Healthcare Conference

Reuters
·
Nov 07

Guardant Health Grants RSUs and Stock Options to New Employees Under Inducement Plan

Reuters
·
Nov 07

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Nov 07

GH Research: Stable Financials and Promising Clinical Progress Support Buy Rating

TIPRANKS
·
Nov 07

Psychedelic: Compass Pathways, GH Research report Q3 earnings

TIPRANKS
·
Nov 07

Guardant Reveal Blood Test Detects Chemotherapy Response Earlier Than Conventional Methods

Reuters
·
Nov 06

Guardant Health: Rise in Tumor Signal Identified Disease Progression up to 18 Months Earlier With Median Lead Time of 2.3 Months

THOMSON REUTERS
·
Nov 06

Guardant Health: Patients Who Experienced Over 98% Reduction in Tumor Signal Saw Most Significant Benefits

THOMSON REUTERS
·
Nov 06

New Study Validates Guardant Reveal Blood Test’s Effectiveness in Monitoring Chemotherapy Response

THOMSON REUTERS
·
Nov 06

GH Research Q3 EPS $(0.23) Beats $(0.24) Estimate

Benzinga
·
Nov 06

GH Research reports Q3 EPS (23c), consensus (23c)

TIPRANKS
·
Nov 06

Press Release: GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates

Dow Jones
·
Nov 06